Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-110 + unmanipulated umbilical cord blood
- Development stage
- Unknown
- Lead developer
- Angiocrine Bioscience
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
AB-110 + unmanipulated umbilical cord blood is a combination cell therapy regimen developed by Angiocrine Bioscience for the treatment of high-risk hematologic malignancies. AB-110 consists of hematopoietic stem and progenitor cells (HSPCs) that have been expanded ex vivo using Angiocrine's proprietary E-CEL (Engineered Colony-forming Endothelial Cells) technology. This technology utilizes human umbilical vein endothelial cells (HUVECs) genetically modified with the adenovirus E4ORF1 gene, which allows the cells to survive and function as a supportive vascular niche without exogenous growth factors. In clinical practice, the expanded AB-110 product is co-infused with a standard, unmanipulated umbilical cord blood unit. The expanded cells in AB-110 are designed to provide rapid, short-term hematopoietic recovery (neutrophils and platelets), while the unmanipulated unit ensures long-term engraftment and immune reconstitution.
- Other names
- E-CELVeraCellE-CEL UVEC expanded cord bloodE4ORF1-engineered endothelial cell expanded cord bloodE-4ORF1-engineered endothelial cell expanded cord bloodE 4ORF1-engineered endothelial cell expanded cord blood
Beyond the preview
Go deeper on AB-110 + unmanipulated umbilical cord blood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-110 + unmanipulated umbilical cord blood.